InsidersTradesSigma
에스케이바이오팜 Stock: price and management transactions · South Korea · DART (FSS)
Follow the 에스케이바이오팜 stock price and the full directors' dealings record of the company, a publicly traded company based in South Korea. Shares are quoted on KR KR, under the supervision of DART (FSS). Operating in the Health Care sector, 에스케이바이오팜 has logged 3 reports. Market capitalisation: €6,312bn. The latest transaction was reported on 31 March 2026 (Sale). Among the most active insiders: SK. Every trade is free.
3
Insider Decl.
n/a
Thresholds
€719m
1 ops.
Buy Volume
n/a
1 ops.
Sell Volume
18Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 5,673 of 28,199 companies
66.7
score / 100
Value40
Quality93
FCF yld2.3%
Earn yld4.2%
EV/EBITDA36.2x
ROE44%
Gross mgn94%
Net mgn38%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 31 March 2026
About 에스케이바이오팜
SK Biopharmaceuticals is a company in the health and pharmaceutical sector, listed on the XKRX exchange. It focuses on developing innovative treatments for neurological disorders.